Research progress of KRAS-targeted therapy for pancreatic ductal adenocarcinama / 中华消化外科杂志
Chinese Journal of Digestive Surgery
;
(12): 116-120, 2018.
Article
Dans Chinois
| WPRIM
| ID: wpr-699081
ABSTRACT
At present,pancreatic ductal adenocarcinama (PDAC) is one of the deadliest malignant solid tumors,with poor prognosis and 5-year survival rate of 5%.Although understanding of the pathogenesis has greatly been improved for nearly two decades,there isn't a breakthrough in clinical therapy of the PDAC,and finding a new and effective therapy is badly needed.Genetic analysis showed that KRAS was one of the earliest and great probability mutated gene in the PDAC,played a significant role in initiation,progression,and metastasis of cancer,and predicted to being a good target of anti-PDAC.But a KRAS-targeted effective drug is lacking in clinic.The direct KRAS-targeted therapy will bright prospects.Meanwhile,locking localization and activity of cell membrane through post-translational modifications to KRAS combined with inhibiting KRAS downstream pathway is a good way of the KRAS-targeted PDAC therapy.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Type d'étude:
Étude pronostique
langue:
Chinois
Texte intégral:
Chinese Journal of Digestive Surgery
Année:
2018
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS